BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
11/7/2024 8:48:05 AM | Browse: 150 | Download: 795
 |
Received |
|
2024-06-25 12:58 |
|
Peer-Review Started |
|
2024-06-25 12:58 |
|
First Decision by Editorial Office Director |
|
2024-08-14 05:14 |
|
Return for Revision |
|
2024-08-14 05:14 |
|
Revised |
|
2024-08-23 07:29 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2024-09-05 02:42 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2024-09-05 09:34 |
|
Articles in Press |
|
2024-09-05 09:34 |
|
Edit the Manuscript by Language Editor |
|
2024-09-21 21:00 |
|
Typeset the Manuscript |
|
2024-10-16 02:41 |
|
Publish the Manuscript Online |
|
2024-11-07 08:48 |
| ISSN |
2220-6124 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Pediatrics |
| Manuscript Type |
Retrospective Study |
| Article Title |
Outcomes of a 12-month course of early and late rituximab BCD020 biosimilar administration in juvenile systemic lupus erythematosus: A retrospective study
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Elvira Kalashnikova, Eugenia Isupova, Ekaterina Gaidar, Natalia Lubimova, Lyubov Sorokina, Irina Chikova, Maria Kaneva, Rinat Raupov, Olga Kalashnikova, Damir Aliev, Inna Gaydukova and Mikhail Kostik |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Ministry of Science and Higher Education of the Russian Federation |
075-15-2022-301 |
| Russian Science Foundation |
22-45-08004 |
|
| Corresponding Author |
Mikhail Kostik, MD, PhD, Professor, Hospital Pediatry, Saint-Petersburg State Pediatric Medical University, Lytovskaya 2, Saint Petersburg 194100, Sankt-Peterburg, Russia. kost-mikhail@yandex.ru |
| Key Words |
Systemic lupus erythematosus; Rituximab; Rituximab BCD020 biosimilar; Anti-CD-20; Biologic; Children |
| Core Tip |
Systemic lupus erythematosus in children is a severe life-threatening disease, that requires systemic immune-suppressive therapy. Early biologic treatment in children with systemic lupus erythematosus can provide faster remission with a better corticosteroid-sparing effect. |
| Publish Date |
2024-11-07 08:48 |
| Citation |
Kalashnikova E, Isupova E, Gaidar E, Lubimova N, Sorokina L, Chikova I, Kaneva M, Raupov R, Kalashnikova O, Aliev D, Gaydukova I, Kostik M. Outcomes of a 12-month course of early and late rituximab BCD020 biosimilar administration in juvenile systemic lupus erythematosus: A retrospective study. World J Nephrol 2024; 13(4): 98393 |
| URL |
https://www.wjgnet.com/2220-6124/full/v13/i4/98393.htm |
| DOI |
https://dx.doi.org/10.5527/wjn.v13.i4.98393 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
